New Alzheimer's drug 8M2D enters first human safety trials
NCT ID NCT07568041
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new drug called 8M2D for the first time in people. The goal is to see if it is safe and tolerable in healthy adults and in people with early Alzheimer's disease. Researchers will also check if 8M2D can lower amyloid beta, a protein linked to Alzheimer's. The study involves 54 participants and will help decide the right dose for future trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE(AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Zapping the brain to boost memory and mood in Alzheimer's
- Tailored sound waves may sharpen the mind
- Blood test could revolutionize Alzheimer's diagnosis, reducing need for spinal taps and scans
- Blood test could revolutionize Alzheimer's diagnosis at your Doctor's office
- Pink noise at night may boost memory in early Alzheimer's
- Simple blood test could spot Alzheimer's before symptoms worsen